Industry News and Articles
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS)…
Latest posts
Tracking The Pulse Of The Philadelphia Life Sciences Industry
Sarian Bio Tech Bulletin 2019-Vol 6 Click the link to view the PDF file. …
Local Company Spotlight: Cognizance Biomarkers
Cognizance Biomarkers is answering the question: “Did you have a seizure?” Cognizance Biomarkers, LLC, a…
Philadelphia Is The Location That I Have Chosen
Hyman Roth said to Michael Corleone in Godfather II, “This is the business we have…
The Life Sciences Executive Network At Sarian Strategic Partners Presents Biotech Bulletin | 2019, Volume 4
Stay up to date on the pulse of the Philadelphia Life Sciences industry with our…
The Pre-Transaction Wealth Optimization Process: Pre-Transaction Planning Concepts to Help you Keep More of What you Have Built Before and After a Liquidity Event
The Liquidity Event: Seizing the Opportunity A liquidity event is very uncommon—often a once…
Debt and Liability Management: Key Issues and Considerations for Entrepreneurs
Greg Sarian of the Sarian Group at Hightower shares his advice on Debt and Liability…
